Over the past 12 months, 0 insiders at Verve Therapeutics, Inc. filed 0 open-market SEC Form 4 transactions on VERV: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 2, 25 | Andrew D. AsheSee Remarks | SELL | 2.7K | $4.15 | $11K |
| Apr 2, 25 | Allison DorvalChief Financial Officer | SELL | 3.4K | $4.15 | $14K |
| Apr 2, 25 | Sekar KathiresanChief Executive Officer | SELL | 9.8K | $4.15 | $41K |
| Apr 2, 25 | Troy ListerChief Scientific Officer | SELL | 2.2K | $4.15 | $9K |
| Apr 2, 25 | Joan NickersonChief Administrative Officer | SELL | 2.8K | $4.15 | $12K |
| Apr 2, 25 | Jason PolitiChief Technical Ops. Off. | SELL | 3.2K | $4.15 | $13K |
| Dec 2, 24 | Allison DorvalChief Financial Officer | SELL | 555 | $5.64 | $3K |
| May 14, 24 | Andrew D. AsheSee Remarks | BUY | 76.0K | $6.26 | $476K |
| Apr 2, 24 | Joan NickersonChief Administrative Officer | SELL | 1.5K | $8.24 | $12K |
| Dec 1, 23 | Krishna YeshwantDirector,TenPercentOwner | BUY | 1.80M | $10.00 | $18.0M |
| Nov 29, 23 | Allison DorvalChief Financial Officer | SELL | 554 | $11.45 | $6K |
| Dec 1, 22 | Andrew BellingerCSO & CMO | SELL | 865 | $22.95 | $20K |
| Nov 29, 22 | Allison DorvalChief Financial Officer | SELL | 554 | $22.10 | $12K |
| Nov 4, 22 | Alphabet Inc.Other | SELL | 47.7K | $32.90 | $1.5M |
| Nov 4, 22 | Krishna YeshwantDirector,TenPercentOwner | SELL | 47.7K | $32.90 | $1.5M |
| Nov 3, 22 | L.p. Gv 2017Other | SELL | 25.5K | $33.84 | $846K |
| Nov 3, 22 | Krishna YeshwantDirector,TenPercentOwner | SELL | 25.5K | $33.84 | $846K |
| Nov 2, 22 | L.p. Gv 2017Other | SELL | 10.4K | $36.78 | $376K |
| Nov 2, 22 | Krishna YeshwantDirector,TenPercentOwner | SELL | 10.4K | $36.78 | $376K |
| Nov 1, 22 | L.p. Gv 2019 GpOther | SELL | 29.3K | $38.64 | $1.1M |
| Nov 1, 22 | Krishna YeshwantDirector,TenPercentOwner | SELL | 29.3K | $38.64 | $1.1M |
| Oct 31, 22 | L.p. Gv 2019 GpOther | SELL | 23.7K | $40.64 | $906K |
| Oct 31, 22 | Krishna YeshwantDirector,TenPercentOwner | SELL | 23.7K | $40.64 | $906K |
| Oct 28, 22 | Andrew BellingerCSO & CMO | SELL | 10.0K | $39.90 | $399K |
| Oct 3, 22 | Sekar KathiresanChief Executive Officer | SELL | 28.9K | $34.97 | $955K |
| Sep 23, 22 | Andrew BellingerCSO & CMO | SELL | 36.8K | $36.03 | $1.3M |
| Aug 10, 22 | Sekar KathiresanChief Executive Officer | SELL | 50.0K | $29.90 | $1.5M |
| Jul 20, 22 | Andrew BellingerCSO & CMO | SELL | 20.0K | $34.90 | $698K |
| Jul 19, 22 | Sekar KathiresanChief Executive Officer | SELL | 50.0K | $29.90 | $1.5M |
| Jul 13, 22 | Andrew BellingerCSO & CMO | SELL | 10.0K | $24.90 | $249K |
| Jul 12, 22 | Fmr LlcTenPercentOwnerOther | SELL | 100.0K | $22.04 | $2.0M |
| Jul 1, 22 | Fmr LlcTenPercentOwnerOther | SELL | 38.8K | $15.66 | $607K |
| Jun 30, 22 | Fmr LlcTenPercentOwnerOther | SELL | 18.8K | $15.21 | $286K |
| Jun 29, 22 | Fmr LlcTenPercentOwnerOther | SELL | 30.4K | $15.60 | $474K |
| May 12, 22 | Burt A AdelmanDirector | BUY | 10.0K | $12.15 | $122K |
| Mar 15, 22 | Burt A AdelmanDirector | BUY | 4.0K | $21.38 | $86K |
| Mar 9, 22 | Fmr LlcTenPercentOwnerOther | SELL | 4.0K | $29.01 | $115K |
| Feb 9, 22 | Fmr LlcTenPercentOwnerOther | SELL | 13.2K | $29.46 | $389K |
| Feb 1, 22 | Fmr LlcTenPercentOwnerOther | SELL | 35.6K | $29.04 | $1.0M |
| Jan 27, 22 | Fmr LlcTenPercentOwnerOther | SELL | 8.7K | $30.02 | $256K |
| Jan 26, 22 | Fmr LlcTenPercentOwnerOther | SELL | 89.0K | $31.96 | $2.8M |
| Jan 4, 22 | Sekar KathiresanChief Executive Officer | SELL | 1.9K | $39.90 | $75K |
| Dec 28, 21 | Sekar KathiresanChief Executive Officer | SELL | 6.7K | $39.90 | $267K |
| Dec 27, 21 | Sekar KathiresanChief Executive Officer | SELL | 36.4K | $42.21 | $1.5M |
| Dec 23, 21 | Sekar KathiresanChief Executive Officer | SELL | 57.0K | $39.90 | $2.3M |
| Dec 22, 21 | Andrew BellingerChief Scientific Officer | SELL | 8.2K | $39.37 | $315K |
| Dec 22, 21 | Sekar KathiresanChief Executive Officer | SELL | 31.1K | $39.78 | $1.2M |
| Dec 2, 21 | Burt A AdelmanDirector | BUY | 4.7K | $31.34 | $147K |
| Dec 2, 21 | Andrew D. AsheSee Remarks | BUY | 4.0K | $32.10 | $128K |
Over the past 12 months, insiders at Verve Therapeutics, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on VERV, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market VERV insider purchase in our data was $18.0M by Krishna Yeshwant, Director,TenPercentOwner, filed on Dec 1, 23.
0 different insiders at Verve Therapeutics, Inc. filed open-market SEC Form 4 transactions on VERV over the last 12 months.
InsiderTape plots every VERV insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Verve Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →